PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Dosulepin hydrochloride - Pain (Neuropathic)

PAD Profile : Dosulepin hydrochloride - Pain (Neuropathic)

Keywords :
Dothiepin, tricyclic antidepressants, tricyclics, TCAs
Brand Names Include :
Prothiaden

Traffic Light Status

Status 1 of 1.

Status :
Non Formulary
Formulations :
  • Not Specified
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
NFD1
Un
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
03 June 2020
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

At the Surrey and North-West Sussex Area Prescribing Committee (APC) held in June 2020, it was decided that all BLACK status drugs would have their review dates extended for 5 years without the need for a review.

If a clinician or provider wishes to change the traffic light status of any BLACK drug then they will need to submit a paper for change as per usual APC process.

02 November 2016
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN does not recommend the use of ‘off label’ dosulepin for the treatment of neuropathic pain. See locally agreed neuropathic pain guidelines below

Associated BNF Codes

04. Central Nervous System
04.07.03. Neuropathic pain
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More